ADHD and Anxiety Shared Signs Different Drivers and Care Planning

Reviewd By Burton J. Tabaac, MD, FAHA"

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

ADHD and anxiety can overlap because both can cause restlessness, poor focus, sleep problems, irritability and task avoidance. The difference usually comes from the driver behind the symptom. ADHD often starts with attention regulation, time, impulse control and executive function problems. Anxiety often starts with fear, worry, threat scanning, avoidance and physical tension. You can also have both, which means care should address each pattern directly.

You may struggle to tell the difference because the surface signs can look similar. You may feel unable to focus at work, avoid a task, feel tense before a deadline or lie awake thinking about everything you have not finished. ADHD can create repeated problems that lead to anxiety. Anxiety can consume attention and make ADHD symptoms worse.

A careful assessment looks at the full pattern. A clinician may ask when symptoms began, what happens before symptoms appear, how long they last, where they show up and what they affect. The answer may be ADHD, anxiety, both conditions or another issue such as sleep loss, depression, trauma, substance use or a medical problem.

Care planning should be practical. If ADHD drives missed tasks, you may need ADHD treatment, routines, reminders and task supports. If anxiety drives worry and avoidance, you may need therapy for anxiety, exposure based work, relaxation skills or medication discussions with a clinician. If both are present, the plan should treat both without treating one as the full answer.

Fast answer for ADHD and anxiety

ADHD and anxiety share signs such as poor focus, restlessness, irritability, sleep problems and avoidance. ADHD usually involves persistent problems with attention, time, task starts, organization and impulse control that began earlier in life. Anxiety usually involves excessive worry, fear, tension, threat scanning and avoidance that may focus on school, work, health, relationships or safety.

You can have ADHD without anxiety. You can have anxiety without ADHD. You can also have both. According to the Centers for Disease Control and Prevention (CDC), many children with ADHD have another condition as well, and anxiety is one of the common coexisting conditions. Adult ADHD can also appear with anxiety, depression, sleep problems or substance risk.

The key question is what drives the symptom. If you cannot focus because your mind keeps returning to worry, anxiety may be a major driver. If you cannot focus because your attention shifts, tasks disappear and time feels unreliable even when you are not worried, ADHD may be a major driver. If missed tasks create worry, and worry then worsens focus, both patterns may be active.

You should seek assessment when symptoms affect school, work, home routines, relationships, sleep or safety. A clinician can review ADHD symptoms, anxiety symptoms, medical history, sleep, mood, substance use, trauma history and daily impairment.

Shared signs like restlessness and poor focus

ADHD and anxiety can look similar in daily life. Both can make it hard to concentrate, sit still, sleep, finish work and stay calm under pressure. The same behavior can have different causes.

Poor focus is a common overlap. With ADHD, your attention may shift away from the task even when you are not worried. You may lose track of steps, forget what you were doing, miss details or start too late. With anxiety, your focus may be pulled toward threat, worry or possible mistakes. You may reread the same message because you fear sending the wrong reply.

Restlessness can also happen in both conditions. ADHD restlessness may feel like a need for movement, stimulation or task switching. Anxiety restlessness may feel like being on edge, tense or unable to settle because something feels unsafe or unresolved.

Irritability can appear in both patterns. ADHD may create irritability when tasks are too long, transitions happen too fast or impulse control is low. Anxiety may create irritability when worry is high, reassurance is not enough or uncertainty feels hard to tolerate.

Sleep problems are another overlap. ADHD can delay bedtime because stopping tasks is hard, time slips away or the mind becomes active at night. Anxiety can delay sleep because worry, fear or physical tension keeps you awake.

Why overlap can lead to missed diagnosis

A person with ADHD may be treated for anxiety because the visible problem is worry about missed tasks. A person with anxiety may be assessed for ADHD because poor focus is the main complaint. Some people have both and need both addressed.

A good assessment avoids rushing. It asks about childhood patterns, task history, worry patterns, sleep, mood, trauma, substance use and real life impairment.

What to track before an appointment

Track the situation, the thought, the body response and the action. For example, note if you avoided an email because you forgot it, because it felt too boring, because you feared the reply or because the task had too many unclear steps.

This kind of record helps separate ADHD driven patterns from anxiety driven patterns.

ADHD-driven stress cycles

ADHD can create stress when repeated attention and executive function problems affect daily life. You may miss deadlines, forget messages, lose items, arrive late, interrupt others or leave tasks unfinished. These problems can lead to worry, embarrassment and conflict.

The stress cycle often starts with a task that is hard to start. You delay it, the deadline gets closer, pressure rises and anxiety appears. You may then rush, make mistakes or avoid the task because it feels emotionally loaded. The next time a similar task appears, your body remembers the stress.

ADHD can also make life feel unpredictable. You may not trust your memory, time sense or ability to follow through. This can lead to constant checking, overpreparing or worry that something has been missed. In that case, anxiety may grow from real repeated ADHD related problems.

Children with ADHD may become anxious after repeated correction at school. A child who forgets homework, loses materials or interrupts often may begin to fear classwork or teacher feedback. Teens may worry about falling behind, being judged by peers or disappointing family. Adults may worry about job loss, unpaid bills, relationship strain or missed responsibilities.

Signs that ADHD may be the first driver

ADHD may be a major driver when symptoms began in childhood, appear across many settings and include attention, time, organization and impulse control problems even when worry is not high.

You may notice these patterns.

  • You lose track of tasks that do not make you anxious
  • You forget steps even when you feel calm
  • You start late because time does not feel real
  • You interrupt before you can pause
  • You avoid tasks because they feel unclear or boring
  • Worry rises after repeated missed tasks

The anxiety may still be real. The care plan may need to treat ADHD patterns that keep feeding it.

Anxiety-driven worry cycles

Anxiety can create its own cycle. You may worry about mistakes, judgment, health, school, work, money or relationships. The worry may feel hard to control. Your body may feel tense, restless, tired or keyed up. You may avoid the task or situation that triggers fear.

Anxiety can make focus worse because worry takes up mental space. You may open a work task and spend the time thinking about possible failure. You may try to write a message and keep rewriting it because it might sound wrong. You may avoid making a phone call because you fear the response.

Avoidance can provide short term relief. You skip the call, close the email or delay the appointment. The relief teaches your brain to avoid again. Over time, the task may feel harder because it becomes linked with fear.

Physical symptoms can also be part of anxiety. You may feel muscle tension, stomach upset, sweating, trembling, fast heartbeat or shortness of breath. These symptoms can make it harder to sit with a task long enough to finish it.

Signs that anxiety may be the first driver

Anxiety may be a major driver when worry, fear or threat scanning appears before poor focus or avoidance. You may focus poorly because your mind keeps returning to what could go wrong.

You may notice these patterns.

  • You avoid tasks because of fear or worry
  • You reread or recheck because mistakes feel dangerous
  • You feel tense even when no task is due
  • You seek reassurance often
  • You sleep poorly because worry stays active
  • Your attention improves when worry is lower

A clinician can help decide if anxiety treatment should come first, happen alongside ADHD treatment or follow ADHD stabilization.

Diagnosis questions that separate the pattern

Assessment should look at timing, triggers and impairment. You can prepare by thinking through specific questions before the visit.

When did the symptoms begin. ADHD symptoms usually begin in childhood, even if diagnosis happens later. Anxiety can also begin early, but it may start after stress, trauma, life changes or repeated failures.

What happens first. If missed tasks, poor planning or impulsive choices happen first and worry follows, ADHD may be feeding anxiety. If worry, fear or physical tension happens first and blocks action, anxiety may be driving the problem.

Where do symptoms appear. ADHD often appears across settings, such as home, school, work and relationships. Anxiety may be broad or may cluster around specific triggers such as social situations, health fears, performance, separation or panic sensations.

What is avoided. ADHD avoidance often comes from boredom, unclear steps, low reward, overwhelm or past failure. Anxiety avoidance often comes from fear, uncertainty, judgment or danger signals.

What helps. ADHD may improve with structure, medication when prescribed, movement, written cues and short task starts. Anxiety may improve with cognitive behavioral therapy, exposure based work, relaxation skills, worry practice and medication discussions when needed.

Questions your clinician may ask

A clinician may ask these kinds of questions.

  • Did attention problems begin before age twelve
  • Do symptoms happen in more than one setting
  • Do you worry most days or only after tasks are missed
  • Do you avoid tasks because they are boring, unclear or frightening
  • Do you feel physical anxiety symptoms
  • Do you have panic attacks
  • How is your sleep
  • Do you use alcohol, cannabis, nicotine or other substances to cope
  • Do you have depression symptoms
  • Do you have trauma symptoms
  • What has helped before

Clear answers can help the clinician avoid treating one condition while missing another.

Treatment planning when both are present

When ADHD and anxiety are both present, the care plan should address both patterns. The sequence depends on symptom severity, safety and daily impairment.

Medication may be discussed for ADHD, anxiety or both. ADHD medication can reduce ADHD symptoms for many people, but it should be prescribed and monitored by a qualified clinician. Anxiety medication options should also be discussed with a clinician, especially if panic, severe worry or sleep problems are present.

Therapy can help both conditions. Cognitive behavioral therapy can address task avoidance, worry loops, perfectionism, planning, emotional reactions and daily routines. Exposure based therapy may help anxiety driven avoidance when it fits the diagnosis. ADHD skills training may help calendars, reminders, time supports, task starts and follow through.

Sleep care is often needed. Poor sleep can worsen attention and anxiety. You may need a consistent wake time, a bedtime shutdown routine, reduced late night stimulation and medical review for insomnia, sleep apnea or medication timing concerns.

Daily tools can reduce ADHD driven anxiety. Use one task list, one calendar, visible cues, short starts, timer based work blocks and written instructions. When tasks are visible and smaller, they may trigger less worry.

Anxiety tools can reduce worry driven avoidance. You may learn to label worry, tolerate uncertainty, reduce reassurance cycles and approach feared tasks in planned steps. This work should be guided by a qualified clinician when symptoms are strong.

When safety comes first

Seek urgent help if you have suicidal thoughts, self harm urges, threats of serious harm, psychosis, mania symptoms, severe substance risk, chest pain, fainting or any immediate safety concern. Routine ADHD or anxiety assessment can continue after safety needs are addressed.

Substance risk needs honest discussion

Some people use caffeine, nicotine, cannabis, alcohol or other substances to manage focus, restlessness, sleep or worry. These can affect symptoms, treatment choice and safety. Tell your clinician what you use and how often you use it. Honest information helps the care plan fit real life.

Psychedelic research has brought serious attention to therapeutic setting, emotional processing and psychological flexibility in mental health care, including anxiety related research. For ADHD with anxiety, current care should still rely on established clinical assessment and monitored treatment, and psilocybin is not an approved ADHD treatment.

Link to Rose Hill anxiety article with a clear role split

A page focused on ADHD and anxiety should explain overlap, symptom drivers and care planning when both patterns may be present. A broader anxiety resource can cover anxiety symptoms, therapy options, lifestyle supports and plant based research questions in more depth. For that role split, the page on natural remedies for anxiety can support readers who need a wider anxiety focused resource while this page stays centered on ADHD and anxiety overlap.

Conclusion

As you review ADHD and anxiety, symptom overlap and current research limits, we at Rose Hill Life Sciences follow related questions through our work as a psychedelic research organization focused on the production and research of Psilocybe cubensis, with our role at the intersection of science and therapeutic integration reflected in our Massachusetts research work.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.